Evidence map›Paper›PMID 42234943›Full record

ArticleJCO precision oncology2026

Communication With Clinicians and Relatives About Cascade Genetic Testing in Cancer Patients With Germline Pathogenic Variants.

Allison W Kurian, Paul Abrahamse, Allison Furgal, Christine M Veenstra, Rebecca R Courser, Timothy P Hofer, Rachel Hodan, Jennifer L Caswell-Jin, Scarlett L Gomez, Kevin C Ward and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JCO precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Allison W KurianDepartment of Medicine, Stanford University, Stanford, CA.ORCID 0000-0002-6175-9470
Paul AbrahamseDepartment of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, MI.ORCID 0000-0001-7433-153X
Allison FurgalDepartment of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, MI.ORCID 0000-0001-8081-2444
Christine M VeenstraDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI.ORCID 0000-0001-9947-7156
Rebecca R CourserDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI.
Timothy P HoferDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI.ORCID 0000-0003-0434-8787
Rachel HodanCancer Genetics, Stanford Health Care, Stanford, CA.ORCID 0000-0003-2887-4079
Jennifer L Caswell-JinDepartment of Medicine, Stanford University, Stanford, CA.ORCID 0000-0002-5711-8355
Scarlett L GomezDepartment of Epidemiology and Biostatistics and Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA.ORCID 0000-0002-5143-4867
Kevin C WardDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA.ORCID 0000-0001-5893-6192
Ann S HamiltonDepartment of Population and Public Health Sciences, Keck School of Medicine, Los Angeles, CA.ORCID 0000-0001-5898-2308
Lihua LiuDepartment of Population and Public Health Sciences, Keck School of Medicine, Los Angeles, CA.ORCID 0000-0003-2252-8407
Lawrence C AnDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI.ORCID 0000-0001-9861-1800
Steven J KatzDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI.ORCID 0000-0002-1151-861X

Funding

XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Eric R. Fearon · 1988 to 2026
$178.2M
A population-based virtual solution to reduce gaps in genetic risk evaluation and management in families at high risk for hereditary cancer syndromes: The Georgia-California GeneLINK TrialU01CA254822 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI AN, LAWRENCE CHIN-I, KATZ, STEVEN J. · 2020 to 2024
$3.7M
Personalizing genetic test results management and outcomes after diagnosis of cancer: the Georgia-California SEER Genelink StudyR01CA283207 · NCI · STANFORD UNIVERSITY · PI ALLISON W. KURIAN, Steven J. Katz · 2024 to 2026
$2.0M
NCI NIH HHS P30 CA046592NCI NIH HHS R01 CA283207NCI NIH HHS U01 CA254822
6 · The paper itself

Abstract

purposeGermline testing is underutilized and varies by cancer diagnosis. We hypothesized that patient and clinician involvement in cascade testing of relatives varies by the cancer susceptibility (breast

methodsAll patients diagnosed with cancer in Georgia or California during 2018-2019 and reported to SEER registries, who were linked to a pathogenic variant (PV) result from testing laboratories, were surveyed 4.5 years postdiagnosis about (1) clinician involvement in result communication to relatives, (2) attitudes about result communication, (3) result communication to relatives, and (4) relatives' testing. PVs were categorized by primary association with breast (

resultsA total of 4,080 patients were surveyed; 2,183 responded (53.5%). Most had PVs associated with breast (83.4%) versus GI cancers (16.6%). Most (85.0%) reported a genetic counseling visit. Genetic counselors were most involved in encouraging family communication (71.5%,

conclusionPatients with cancer are motivated to communicate PV results to relatives. However, few clinicians are involved and relatives' testing remains low. Novel care delivery models are needed to advance cascade testing and precision risk reduction.

Indexed as

CommunicationFamilyGenetic TestingGerm-Line MutationNeoplasmsAdultAgedFemaleGenetic Predisposition to DiseaseHumansMaleMiddle Aged

Identifiers

PMID42234943
PMCPMC13314380

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.